Amneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2026 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 0.930-1.030 for the period, compared to the consensus EPS estimate of 0.920. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.2 billion.

Amneal Pharmaceuticals Price Performance

AMRX stock traded down $0.68 on Friday, reaching $13.81. 3,912,425 shares of the company traded hands, compared to its average volume of 2,791,902. The firm has a fifty day simple moving average of $13.72 and a 200-day simple moving average of $11.69. The company has a market cap of $4.34 billion, a P/E ratio of 690.85 and a beta of 1.36. Amneal Pharmaceuticals has a one year low of $6.68 and a one year high of $15.42.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on AMRX shares. Truist Financial set a $15.00 price target on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 7th. Barclays began coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $15.00 target price for the company. Piper Sandler reiterated an “overweight” rating and set a $13.00 price target (up from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Amneal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.80.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Amneal Pharmaceuticals by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company’s stock worth $793,000 after purchasing an additional 4,178 shares during the period. Millennium Management LLC boosted its stake in shares of Amneal Pharmaceuticals by 32.6% in the 1st quarter. Millennium Management LLC now owns 2,087,398 shares of the company’s stock worth $17,492,000 after buying an additional 512,842 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Amneal Pharmaceuticals in the first quarter worth $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Amneal Pharmaceuticals by 5.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company’s stock valued at $2,807,000 after acquiring an additional 16,536 shares during the last quarter. Finally, Creative Planning lifted its holdings in Amneal Pharmaceuticals by 61.9% in the second quarter. Creative Planning now owns 23,896 shares of the company’s stock valued at $193,000 after acquiring an additional 9,136 shares during the period. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.